Huntington's Disease Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.A Study to Evaluate BV-101 Striatal Administration in Adults With Early Manifest Huntington's Disease
Condition: Huntington Disease Intervention: Genetic: BV-101 Gene Therapy Sponsor: Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2022 Category: Research Source Type: clinical trials
PhI/II Dose-Finding Study to Evaluate BV-101 Striatal Administration in Adults With Early Manifest Huntington's Disease
Condition: Huntington Disease Intervention: Genetic: BV-101 Gene Therapy Sponsor: Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2022 Category: Research Source Type: clinical trials
Clinicopathological MRI and CSF Correlates in Huntington's Disease.
Condition: Huntington Disease Interventions: Diagnostic Test: 7T MRI-scan; Diagnostic Test: CSF collection via lumbar puncture; Diagnostic Test: Blood withdrawal; Diagnostic Test: Clinical measures Sponsors: Leiden University Medical Center; Brighton & Sussex Medical School; University of Ulm Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 9, 2022 Category: Research Source Type: clinical trials
